• Conducted scientific and market due diligence on 50+ biotech firms, including T cell therapy landscape analysis for Swarm Oncology, to identify cross-border partnership and investment opportunities
• Developed 10+ pitch decks and pipeline evaluations supporting in/out-licensing and fundraising projects across the U.S., China, and Europe
• Analyzed global biopharma market and capital trends, summarizing insights that informed prospect targeting and client engagement strategies

• Awarded 2023 Global Pfizer Best Practice - Access Acceleration for CIBINQO®
• • Led access strategy that achieved reimbursement and pricing approval 6 months ahead of standard timeline, through close collaboration with global HEOR, commercial, medical, and public affairs teams
  • Secured listing price premiums through cost-effectiveness modeling, demonstrating compelling economic value to the national payer
• Led cross-functional and external stakeholder alignment across regulatory, medical, commercial, and advocacy partners, ensuring launch readiness and public awareness for new immunology products and PCV20
• Expanded reimbursement scope of atopic dermatitis by crafting value propositions that integrated unmet needs and clinical evidence, successfully negotiating with the national payer to broaden patient access
• Developed simulation models to assess financial impact of biosimilar-favoring policies, enabling proactive mitigation strategies to protect branded biologics portfolio positioning

• Developed CEA and pricing models across cardiovascular and respiratory portfolios, including Enerzair® , where the strategy led to a 2% price markup approved by the national payer
• Conducted real-world outcomes research using Taiwan’s nationwide claims database (23 million lives) to demonstrate clinical benefits of Entresto® in heart failure care
• Organized and led International HTA Workshop (100+ attendees), including Director-General and senior officers from the national payer and HTA agency, to strengthen policy dialogue and payer engagement
• Co-authored policy white papers on cardiovascular disease management, enhancing payer education and disease awareness - "Shaping Cardiovascular Disease Access Policy Landscape"

• Conducted 20+ CEAs and budget impact analysis annually and authored HTA reports for new drug reimbursement applications, informing payer decisions and enabling access for 600,000+ patients
• Developed Horizon Scanning system to support national payer in proactive budget planning and allocation
• Accelerated pneumococcal vaccine policy implementation in high-risk populations by evaluating clinical outcomes and cost-effectiveness, informing national rollout decisions
• Facilitated Pharmacoeconomics Workshops for pharmaceutical professionals, delivering theoratical and hands-on training on CEA model development using TreeAge and Excel
• Published HEOR studies and presented findings at international conferences (HTAsiaLink, ISPOR Asia), showcasing analytical and effective scientific communication.

• Performed real-world data analysis using SAS on hospital electronic medical records (EMR), including data cleaning, regression modeling, and statistical interpretation
• Authored a propensity-score matched cohort study examining renal protection effects of medications hyperuricemia patients, contributing to evidence-based clinical recommendations
• Conducted EQ-5D interviews with pediatric CKD patients as part of a quality-of-life study, also leading IRB submission preparations and developing study protocol to ensure ethical and methodological rigor
• Participated in the national EQ-5D-5L validation study in Taiwan (Lin et al., 2018), assisting with survey implementation and data quality monitoring across diverse population groups

• Concentration: Health Systems and Policy | Certificate: Public Health Economics
• Selected Coursework & Training:
  • Pharmacoepidemiology: RCTs, Observational Studies, Meta-analysis, Systematic Review
  • Biostatistics & Tools: R, SAS, SPSS
  • Policy & Systems: U.S. Healthcare System, Health Policy, Epidemiology of Infectious Disease, Health Advocacy
• Research Project: "Specialty Drugs Cost, Utilization and Policy Evaluation"
• Capstone Field Project (Lao PDR): "Private Pharmacies as First Points of Healthcare Access: Participatory Action Research for Good Pharmacy Practice Implementation in the Lao PDR"
• Practicum (Baltimore, MD): "Healthcare for the Homeless" - Designed questionnaires, conducted interviews and co-developed practical solutions to streamline referral pathways
• Leadership: Secretary of the Anna Baetjer Society for Public Health Practice

• Thesis: "The effect of febuxostat and other urate-lowering agents on uric acid management and renal outcome in patients with chronic kidney disease"

• Licensed Pharmacist, Taiwan Ministry of Health and Welfare (July 2014)

Sci Rep. 2020 Jul 1;10(1):10734

PLoS One. 2019 Aug 26;14(8):e0221504

Curr Med Res Opin. 2020 Oct;36(10):1619-1626